L Number	Hits	Search Text	DB	Time stamp
1	1620	544/262, 514/258	USPAT	2003/05/28 11:56
2	330	pyrazolopyrimidine$	USPAT	2003/05/28 11:57
3	52	(544/262, 514/258) and pyrazolopyrimidine$	USPAT	2003/05/28 11:57

=>
Uploading 09815310.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:47:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 481 TO ITERATE

100.0% PROCESSED 481 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8305 TO 10935
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:47:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9911 TO ITERATE

100.0% PROCESSED 9911 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

L3 16 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 148.55 148.76

FILE 'CAPLUS' ENTERED AT 09:48:05 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d hist

(FILE 'HOME' ENTERED AT 09:46:52 ON 28 MAY 2003)

FILE 'REGISTRY' ENTERED AT 09:47:00 ON 28 MAY 2003
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 16 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:48:05 ON 28 MAY 2003
L4 3 S L3

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.83 149.59

FILE 'CAPLUS' ENTERED AT 09:49:20 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 27 May 2003 (20030527/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L5 3 L3

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:132148 CAPLUS
DOCUMENT NUMBER: 136:318825
TITLE: Pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives as selective inhibitors of the EGF receptor tyrosine kinase
AUTHOR(S): Caravatti, G.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Furet, P.; Lydon, N.; O'Reilly, T.; Traxler, P.
CORPORATE SOURCE: TA Oncology, Novartis Pharma AG, Basel, CH-4002, Switz.
SOURCE: ACS Symposium Series (2001), 796(Anticancer Agents), 231-244
CODEN: ACSMC8; ISSN: 0097-6156
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB The EFG receptor tyrosine kinase (EGFR) is an attractive target for the development of agents directed against tumors which either overexpress the EGFR or which have a mutated or amplified gene encoding the EGFR. Several ATP-competitive inhibitors of this kinase have shown promising in vitro and in vivo efficacy and are currently in different stages of clin. development. One of them is PKI166, a pyrrolo[2,3-d]pyrimidine, which has been selected from a large series of pyrrolo[2,3-d]pyrimidines and structurally related pyrazolo[3,4-d]pyrimidines. The discovery and preclin. data of PKI166 are summarized.
IT **205451-81-6 410524-77-5**
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivs. as selective inhibitors of the EGF receptor tyrosine kinase)
RN 205451-81-6 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-chlorophenyl)-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 410524-77-5 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-chlorophenyl)-3-(1-piperazinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:219810 CAPLUS
DOCUMENT NUMBER: 128:270610
TITLE: Preparation of pyrazolo[3,4-d]-3,4-diamines as epidermal growth factor receptor 2 antagonists
INVENTOR(S): Bold, Guido; Frei, Jorg; Lang, Marc; Traxler, Peter
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Bold, Guido; Frei, Jorg; Lang, Marc; Traxler, Peter
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814450	A1	19980409	WO 1997-EP5369	19970930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,				

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9748642	A1	19980424	AU 1997-48642	19970930
AU 720135	B2	20000525		
EP 929553	A1	19990721	EP 1997-911163	19970930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001501216	T2	20010130	JP 1998-516231	19970930
US 6251911	B1	20010626	US 1999-269823	19990401

PRIORITY APPLN. INFO.: CH 1996-2399 A 19961002
WO 1997-EP5369 W 19970930

OTHER SOURCE(S): MARPAT 128:270610

GI



I

AB Title compds. [I; R = NHZR1; R1 = (un)substituted Ph; R2 = H and R3 = COR4,(un)substituted alkyl, C6H4CH2R5, etc.; NR2R3 = heterocyclyl; R4 = alkyl(amino), NHCH2Ph, pyridylmethylamino, Ph, heterocyclyl, etc.; R5 = carboxyalkanoylamino, NHCO2CH2Ph, NHCONH2, etc.; Z = bond, CH2, alkylidene] were prepd. Thus, (MeS)2C:C(CN)2 was aminated by PhCH2NH2and the product cyclocondensed with H2NNH2 to give 5-amino-3-benzylamino-1H-pyrazole-4-carbonitrile which was cyclocondensed with 3-ClC6H4NH2 to give I (R = NHC6H4Cl-3, R2 = H)(II; R3 = CH2Ph). The latter was converted in 2 steps to II (R3 = COCMe3). Data for biol. activity of I were given.

IT **205451-81-6P 205451-82-7P 205451-83-8P 205451-84-9P 205451-85-0P 205451-86-1P 205451-87-2P 205451-88-3P 205451-89-4P 205451-90-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazolo[3,4-d]-3,4-diamines as epidermal growth factor receptor 2 antagonists)

RN 205451-81-6 CAPLUS

CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-chlorophenyl)-3-(4-morpholinyl)-(9CI) (CA INDEX NAME)



RN 205451-82-7 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-chloro-4-fluorophenyl)-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 205451-83-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 205451-84-9 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-chlorophenyl)-3-(1-piperazinyl)-

, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 205451-85-0 CAPLUS
CN Piperazine, 1-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 205451-86-1 CAPLUS
CN Piperazine, 1-benzoyl-4-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 205451-87-2 CAPLUS
CN Piperazine, 1-acetyl-4-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]- (9CI) (CA INDEX NAME)



RN 205451-88-3 CAPLUS
CN Piperazine, 1-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-(2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 205451-89-4 CAPLUS

CN Piperazine, 1-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-(1-oxododecyl)- (9CI) (CA INDEX NAME)



RN 205451-90-7 CAPLUS
CN Piperazine, 1-[4-[(3-chlorophenyl)amino]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1995:582444 CAPLUS
DOCUMENT NUMBER: 123:256664
TITLE: Synthesis of functionalized pyrazoles and pyrazolo[3,4-d]pyrimidines as potential leishmanicides
AUTHOR(S): Ram, Vishnu J.; Haque, Navedul
CORPORATE SOURCE: Med. Chem. Div., Central Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1995), 34B(6), 521-4
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: Publications & Information Directorate, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Various 2-cyano-3-methylthio-3-piperazinylacrylonitriles/acrylamides were prepd. by the reaction of ketene dithioacetals with substituted piperazines. Reaction of said 2-cyano-3-methylthio-3-piperazinylacrylonitriles/acrylamides with hydrazine hydrate gave the resp. pyrazoles which on boiling in formamide gave pyrazolo[3,4-d]pyrimidines. Reaction of 1-(4-carbethoxy-3-methylthio-1H-pyrazol-5-yl)-3-phenylthiourea with hydrazine gave 5-amino-2-methylthio-6-phenylamino-1H-pyrazolo[3,4-d]pyrimidin-4-one. Some of the compds. have been screened for their in vitro leishmanicidal activity.

IT **168849-18-1P 168849-19-2P 168849-20-5P**
168849-21-6P 168849-22-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrazoles and pyrazolo[3,4-d]pyrimidines for treatment of Leishmaniasis)

RN 168849-18-1 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 168849-19-2 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 168849-20-5 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)





RN 168849-21-6 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(4-chlorophenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 168849-22-7 CAPLUS
CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-[4-(3-chlorophenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.03	163.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 09:49:50 ON 28 MAY 2003